Skip Navigation



JAC Advance Access published online on April 29, 2004
Journal of Antimicrobial Chemotherapy, doi:10.1093/jac/dkh231
© 2004 by The British Society for Antimicrobial Chemotherapy
This Article
Right arrow FREE Full Text (PDF) Freely available
Right arrow All Versions of this Article:
53/6/975    most recent
dkh231v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Fryer, J. F. L.
Right arrow Articles by Clark, D. A.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Fryer, J. F. L.
Right arrow Articles by Clark, D. A.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

Received January 29, 2004
Revised March 5, 2004
Accepted March 9, 2004

Original article

Susceptibility of porcine cytomegalovirus to antiviral drugs

Jacqueline F. L. Fryer 1, Paul D. Griffiths 1, Vincent C. Emery 1, Duncan A. Clark 1*

1 Centre for Virology, Department of Infection, Royal Free and University College Medical School of UCL, Hampstead Site, Rowland Hill Street, London NW3 2PF, UK

* To whom correspondence should be addressed. E-mail: d.clark{at}rfc.ucl.ac.uk.


  Abstract

Objectives: Re-activation of porcine cytomegalovirus (PCMV) in the xenograft has been reported in pig-to-baboon models of xenotransplantation and is associated with invasive disease and consumptive coagulopathy. If xenotransplantation of porcine organs into human recipients is to proceed, donor organs will have to be free from a wide range of infectious agents including PCMV. However, it is prudent to characterize the antiviral susceptibility of this virus. We therefore investigated the effect of selected antiviral agents, currently licensed for the treatment of human herpesvirus infections, on PCMV replication.

Methods: Antiviral susceptibility was determined using real-time PCR and indirect immunofluorescence measurements in a porcine fallopian tube cell line infected with PCMV.

Results: PCMV replication was significantly inhibited by ganciclovir and cidofovir (both EC50 < 1 mg/L) and to a lesser extent by foscarnet (EC50 within range 25-50 mg/L) and aciclovir (EC50 > 25 mg/L).

Conclusions: These results show that, if it proves necessary, ganciclovir and cidofovir should be considered as first-line drugs to treat PCMV infections in xenograft recipients.

Key Words: Keywords: xenotransplantation, ganciclovir, cidofovir


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
 Clin. Microbiol. Rev.Home page
M. C.-J. Cheeran, J. R. Lokensgard, and M. R. Schleiss
Neuropathogenesis of Congenital Cytomegalovirus Infection: Disease Mechanisms and Prospects for Intervention
Clin. Microbiol. Rev., January 1, 2009; 22(1): 99 - 126.
[Abstract] [Full Text] [PDF]


Disclaimer: Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.